Why do current melatonin clinical trials show inconsistent cardiovascular results and might higher doses be needed?

Allometric calculations derived from animal models suggest that achieving cytoprotective and anti-inflammatory effects of melatonin in humans may require daily doses of 100 to 200 mg, substantially exceeding the 2 to 10 mg typically utilized in current clinical trials. This dosage discrepancy is proposed as a potential reason for the inconsistent therapeutic outcomes observed in human cardiovascular studies.